Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNTH NASDAQ:MYGN NASDAQ:NTLA NASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$109.89$98.54$47.25▼$111.86$7.15B-0.06933,351 shs511,083 shsMYGNMyriad Genetics$5.99$4.52$3.53▼$8.59$565.74M1.641.58 million shs1.22 million shsNTLAIntellia Therapeutics$17.56$14.13$7.95▼$28.25$2.45B1.776.46 million shs4.16 million shsQDELQuidelOrtho$18.25$13.06$9.92▼$35.58$1.24B0.691.85 million shs1.22 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus0.00%+0.08%+9.62%+44.40%+38.02%MYGNMyriad Genetics0.00%+1.87%+36.14%+26.11%+6.39%NTLAIntellia Therapeutics0.00%+5.28%+34.87%+33.74%+63.65%QDELQuidelOrtho0.00%+32.34%+34.19%+5.80%-39.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$109.89$98.54$47.25▼$111.86$7.15B-0.06933,351 shs511,083 shsMYGNMyriad Genetics$5.99$4.52$3.53▼$8.59$565.74M1.641.58 million shs1.22 million shsNTLAIntellia Therapeutics$17.56$14.13$7.95▼$28.25$2.45B1.776.46 million shs4.16 million shsQDELQuidelOrtho$18.25$13.06$9.92▼$35.58$1.24B0.691.85 million shs1.22 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus0.00%+0.08%+9.62%+44.40%+38.02%MYGNMyriad Genetics0.00%+1.87%+36.14%+26.11%+6.39%NTLAIntellia Therapeutics0.00%+5.28%+34.87%+33.74%+63.65%QDELQuidelOrtho0.00%+32.34%+34.19%+5.80%-39.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNTHLantheus 2.73Moderate Buy$101.86-7.31% DownsideMYGNMyriad Genetics 2.00Hold$6.508.51% UpsideNTLAIntellia Therapeutics 2.35Hold$20.4616.49% UpsideQDELQuidelOrtho 1.67Reduce$12.38-32.19% DownsideCurrent Analyst Ratings BreakdownLatest MYGN, QDEL, LNTH, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026QDELQuidelOrtho JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$11.00 ➝ $12.006/29/2026QDELQuidelOrtho Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/24/2026MYGNMyriad Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$49.006/15/2026NTLAIntellia Therapeutics New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.006/15/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/15/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/15/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.006/15/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$30.006/15/2026QDELQuidelOrtho Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNTHLantheus$1.54B4.64$6.39 per share17.21$16.43 per share6.69MYGNMyriad Genetics$824.50M0.69$3.77 per share1.59$3.95 per share1.52NTLAIntellia Therapeutics$67.67M36.26N/AN/A$5.80 per share3.03QDELQuidelOrtho$2.73B0.46$19.01 per share0.96$28.27 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNTHLantheus$233.56M$4.1526.4820.43N/A18.05%29.32%15.00%8/5/2026 (Estimated)MYGNMyriad Genetics-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)QDELQuidelOrtho-$1.13B-$17.82N/A7.30N/A-45.57%4.25%1.56%7/29/2026 (Estimated)Latest MYGN, QDEL, LNTH, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2026Q2 2026QDELQuidelOrtho-$0.0174N/AN/AN/A$621.39 millionN/A5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/5/2026Q1 2026MYGNMyriad Genetics-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million5/5/2026Q1 2026QDELQuidelOrtho$0.37-$0.04-$0.41-$1.35$665.23 million$619.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLNTHLantheusN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNTHLantheus0.472.832.64MYGNMyriad Genetics0.362.402.19NTLAIntellia TherapeuticsN/A6.106.10QDELQuidelOrtho1.331.430.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNTHLantheus99.06%MYGNMyriad Genetics99.02%NTLAIntellia Therapeutics88.77%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipLNTHLantheus1.70%MYGNMyriad Genetics1.90%NTLAIntellia Therapeutics3.50%QDELQuidelOrtho1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableMYGNMyriad Genetics2,70094.45 million92.65 millionOptionableNTLAIntellia Therapeutics600139.72 million134.83 millionOptionableQDELQuidelOrtho6,50068.19 million67.44 millionOptionableMYGN, QDEL, LNTH, and NTLA HeadlinesRecent News About These CompaniesQuidelOrtho Stock Short Interest Report | NASDAQ:QDEL | BenzingaJune 30, 2026 | benzinga.comQuidelOrtho to Report Second Quarter 2024 Financial ResultsJune 30, 2026 | businesswire.comDoes QuidelOrtho's (QDEL) Index Exit and New CFO Hint at a Shift in Growth Identity?June 30, 2026 | finance.yahoo.comQuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?June 30, 2026 | zacks.comQDEL Stock Eyes Best Day In Over A Year — Point-Of-Care Sale Talks Ignite RallyJune 29, 2026 | finance.yahoo.comAnalyzing QuidelOrtho (NASDAQ:QDEL) and GE HealthCare Technologies (NASDAQ:GEHC)June 29, 2026 | americanbankingnews.comWall Street Zen Upgrades QuidelOrtho (NASDAQ:QDEL) to HoldJune 28, 2026 | americanbankingnews.comQuidelOrtho plans to sell testing unit for $1.5B: FTJune 27, 2026 | msn.comHead to Head Survey: Bio-Rad Laboratories (NYSE:BIO) vs. QuidelOrtho (NASDAQ:QDEL)June 27, 2026 | americanbankingnews.comQDEL Q1 Deep Dive: Softer Respiratory Demand and China Headwinds Drive Guidance ResetJune 25, 2026 | theglobeandmail.comQuidelOrtho Corporation (NASDAQ:QDEL) Q4 2024 Earnings Call TranscriptJune 25, 2026 | msn.comQuidelOrtho Names New Chief Financial Officer, Plans TransitionJune 23, 2026 | tipranks.comQuidelOrtho Appoints Micah Young as Chief Financial OfficerJune 23, 2026 | prnewswire.comReasons to Retain QuidelOrtho Stock in Your Portfolio for NowJune 17, 2026 | zacks.comIs QuidelOrtho Corp (QDEL) a Bargain After 3.3% Drop? GF Value Says UndervaluedJune 16, 2026 | gurufocus.comQuidelOrtho Shareholders Approve Directors, Pay and AuditorJune 16, 2026 | tipranks.comIs the Options Market Predicting a Spike in QuidelOrtho Stock?June 12, 2026 | zacks.com1 Stock Under $50 with Exciting Potential and 2 Facing ChallengesJune 9, 2026 | finance.yahoo.comA Look At QuidelOrtho (QDEL) Valuation After Recent Share Price Rebound And Longer Term WeaknessJune 8, 2026 | finance.yahoo.comQuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?June 4, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYGN, QDEL, LNTH, and NTLA Company DescriptionsLantheus NASDAQ:LNTH$109.89 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$111.54 +1.65 (+1.50%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Myriad Genetics NASDAQ:MYGN$5.99 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.98 0.00 (-0.08%) As of 07/2/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Intellia Therapeutics NASDAQ:NTLA$17.56 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$17.65 +0.09 (+0.51%) As of 07/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.QuidelOrtho NASDAQ:QDEL$18.25 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$17.86 -0.39 (-2.13%) As of 07/2/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
